Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals

Bellomo, Rinaldo; Uchino, Shigehiko; Naka, Tetsuji; Wan, Li

doi:10.1007/s00134-004-2196-6

Cited by 13 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Titles of the 215 references were scanned for relevance, based on the inclusion criteria, and this identified 48 references as potentially relevant. Abstracts of the 48 references (available from the authors on request) were scanned for relevance, again based on the inclusion criteria, and this identified 12 references [42][43][44][45]53,56,59,[60][61][62][63][64] as potentially relevant. Full-text copy was obtained for each of the 12 references and, of these, six [42][43][44][45]53,56 were already identified from the six previous systematic reviews.…”

Section: Literature Searching/inclusion Criteriamentioning

confidence: 99%

“…Full-text copy was obtained for each of the 12 references and, of these, six [42][43][44][45]53,56 were already identified from the six previous systematic reviews. Of the remaining six, 59-64 one 60 was a duplicate reference and five 59,[61][62][63][64] failed to meet the inclusion criteria for our current review ( Table 5). In summary, no new studies were identified for inclusion to update the existing systematic review.…”

Section: Literature Searching/inclusion Criteriamentioning

confidence: 99%

See 1 more Smart Citation

An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.

Soares

Welton²,

Harrison³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects...

show abstract

Section: Literature Searching/inclusion Criteriamentioning

confidence: 99%

Section: Literature Searching/inclusion Criteriamentioning

confidence: 99%

An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.

Soares

Welton²,

Harrison³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Among 8 articles we chose for the meta-analyses, 4 are written in Japanese and none of them are found on MED-LINE, EMBASE, or Cochrane Database of Systematic Reviews. It was pointed out that RCTs found in ICHUSHI may have good quality by CONSORT checklist but might be ignored by English-speaking investigators (27). In our analyses, extensive literature search was done for both English and Japanese articles.…”

Section: Discussionmentioning

confidence: 99%

Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) in the Treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis

et al. 2010

View full text Add to dashboard Cite

Introduction Sivelestat is neutrophil elastase inhibitor, which is widely used in Japan for the treatment of acute lung injury. However, the clinical efficacy of the medication has not been convincingly demonstrated. Methods We conducted a systematic review and meta-analysis of randomized controlled trials on sivelestat for the treatment of acute lung injury and acute respiratory distress syndrome. Studies were identified using MEDLINE, EMBASE, Cochrane library, conference proceedings, and references of included studies. Authors were contacted if necessary. ICHUSHI, the Japanese database for medical literature and conference proceedings was also used for the search, since many studies on sivelestat were published in Japanese language and not registered in major databases such as MEDLINE. The primary outcome was mortality within 28-30 days after randomization. Relative risks were pooled with the random effect model. Results 8 trials were included in the analysis. There was no difference in mortality within 28-30 days after randomization (relative risk 0.95, 95% confidence interval 0.72 to 1.26). Subgroup analysis conducted only on studies conducted in Japan showed the same result (0.59, 0.28 to 1.28). There was no difference in mechanical ventilation days (standardized mean difference -0.43, -1.12 to 0.27), but sivelestat was associated with a better short term PaO2/FiO2 ratio (0.30, 0.05 to 0.56). Heterogeneity was not significant for the main analysis and funnel plot did not suggest publication bias. Conclusion Sivelestat was not associated with decreased mortality, even when including studies published in Japanese language.

show abstract

“…F i g u r e 1 . Ch e s t CT o n a d mi s s i o n ( A) a n d a f t e r s i v e l e s t a t a n d a n t i t u b e r c u l o s i s t h e r a p y ( B ) among patients with lung injury associated with SIRS (2). Therefore, we believe that sivelestat sodium hydrate combined with antituberculosis therapy presents a novel therapeutic option in the treatment of ARDS due to tuberculosis.…”

Section: The Hematogenous Spread Of Mycobacterium Tuberculosis Causesmentioning

confidence: 99%

Acute Respiratory Failure Associated with Miliary Tuberculosis Successfully Treated with Sivelestat Sodium Hydrate

et al. 2006

View full text Add to dashboard Cite

The hematogenous spread of Mycobacterium tuberculosis causes miliary tuberculosis which is a life-threatening disease that is a recognized cause of acute respiratory distress syndrome (ARDS) (1). The neutrophil elastase inhibitor sivelestat sodium hydrate can effectively treat lung injury associated with systemic inflammatory response syndrome (SIRS) (2). (Fig. 1B). Therefore, antituberculosis therapy was continued to address the miliary tuberculosis. Tuberculosis is uncommon but definite cause of ARDS, which is associated with a high fatality rate (1, 3). Although antituberculosis therapy is the first choice of the treatment for ARDS due to tuberculosis, delays in the diagnosis of tuberculosis and initiation of antituberculosis therapy have been recognized as the main cause of death (3).

show abstract

Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals

Abstract: Despite sound methodology and quality, the information obtained from relatively large Japanese critical care trials is not widely available to English-speaking investigators and therefore might be ignored in meta-analyses.

Cited by 13 publications

References 20 publications

An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.

An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.

Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) in the Treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis

Acute Respiratory Failure Associated with Miliary Tuberculosis Successfully Treated with Sivelestat Sodium Hydrate

Contact Info

Product

Resources

About